Stox
30
Bal Pharma Limited
NSE: BALPHARMA · Unclassified
₹81.55-2.41%06 Nov 2026
Check figures: unusual quarterly results in MAR '25 (₹6.73 cr vs a typical ₹0.52 cr). This may be a filing error (e.g. lakh filed as crore) or a genuine one-off; figures are shown as filed. Trailing-twelve-month figures include it.
Ask the data
Instant answers about Bal Pharma Limited — computed from its filings, no language modelMarket cap₹130 cr
Current price₹81.55
High / Low₹114 / ₹60
P/E18.0
P/B1.58
Book value₹51.6
ROE8.8%
ROCE10.0%
Debt / equity1.94
Dividend yield0.02%
EPS (TTM)₹4.52
Face value₹10
Price & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY18 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 211.8 | 171.1 | 250.5 | 281.2 | 304.2 | 339.2 | 303.1 | 311.7 |
| EBITDA | 17.4 | 4.8 | 24.5 | 23.5 | 25.1 | 31.5 | 29.6 | 31.9 |
| Operating margin | 8.2% | 2.8% | 9.8% | 8.3% | 8.3% | 9.3% | 9.8% | 10.2% |
| Interest | 9.3 | 12.4 | 12.0 | 10.4 | 12.2 | 15.3 | 16.9 | 16.8 |
| Depreciation | 6.8 | 7.7 | 9.5 | 9.0 | 9.1 | 10.1 | 9.8 | 11.1 |
| Profit before tax | 2.9 | -13.5 | 4.1 | 9.2 | 4.8 | 9.1 | 5.1 | 5.9 |
| Tax | 2.5 | -0.6 | -0.6 | 3.5 | 2.1 | 1.6 | -2.1 | -0.4 |
| Net profit | 0.0 | 0.0 | 4.7 | 5.6 | 0.0 | 7.4 | 7.2 | 6.3 |
| EPS ₹ | 0.20 | -8.62 | 3.34 | 3.79 | 1.67 | 4.94 | 4.56 | 3.95 |
| Operating cash flow | — | — | — | 32.0 | 23.0 | 329.2 | 20.7 | 7.9 |
| Capex | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Dividend paid | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total assets | — | — | — | — | 313.2 | 320.4 | 335.7 | 375.5 |
| Equity | — | — | — | — | 63.8 | 69.3 | 77.4 | 82.2 |
Quarterly performance
last 28 quarters · ₹ crore| MAR '18 | SEP '19 | DEC '19 | MAR '20 | JUN '20 | SEP '20 | DEC '20 | MAR '21 | SEP '21 | DEC '21 | MAR '22 | JUN '22 | SEP '22 | DEC '22 | MAR '23 | JUN '23 | SEP '23 | DEC '23 | MAR '24 | JUN '24 | SEP '24 | DEC '24 | MAR '25 | JUN '25 | SEP '25 | DEC '25 | MAR '26 | JUN '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 58.9 | 45.0 | 43.2 | 33.8 | 52.1 | 64.6 | 63.0 | 70.8 | 67.2 | 69.2 | 74.0 | 69.8 | 75.3 | 76.6 | 82.5 | 70.4 | 92.5 | 81.7 | 94.6 | 74.4 | 73.7 | 73.2 | 81.9 | 65.9 | 74.0 | 87.7 | 84.1 | 88.6 |
| Operating profit | 5.8 | 1.8 | 0.7 | 0.6 | 5.1 | 7.1 | 5.9 | 6.3 | 6.3 | 6.2 | 3.5 | 5.0 | 5.8 | 6.2 | 8.2 | 6.4 | 7.7 | 7.8 | 9.6 | 6.5 | 7.7 | 7.8 | 7.6 | 6.1 | 5.7 | 9.6 | 10.6 | 8.0 |
| Operating margin | 9.8% | 4.1% | 1.6% | 1.9% | 9.7% | 11.0% | 9.4% | 9.0% | 9.4% | 9.0% | 4.7% | 7.2% | 7.7% | 8.0% | 9.9% | 9.1% | 8.3% | 9.5% | 10.1% | 8.7% | 10.4% | 10.6% | 9.3% | 9.2% | 7.7% | 10.9% | 12.6% | 9.0% |
| Other income | -0.2 | 0.0 | 0.4 | 1.2 | 0.2 | 0.1 | 0.2 | 0.7 | 0.6 | 0.8 | 3.7 | 0.2 | 0.1 | 0.5 | 0.2 | 0.2 | 0.1 | 0.1 | 2.5 | 0.8 | -0.2 | 0.5 | 1.1 | 0.7 | 1.1 | 0.3 | -0.2 | 0.4 |
| Interest | 2.7 | 3.3 | 2.8 | 3.0 | 2.8 | 3.2 | 2.9 | 3.1 | 2.6 | 2.4 | 2.5 | 2.4 | 2.9 | 3.1 | 3.9 | 3.6 | 3.8 | 3.7 | 4.1 | 4.2 | 3.6 | 5.0 | 4.0 | 4.0 | 3.9 | 4.8 | 4.1 | 4.5 |
| Depreciation | 2.0 | 1.4 | 1.4 | 3.6 | 1.9 | 2.2 | 2.0 | 3.4 | 2.2 | 2.2 | 2.4 | 2.2 | 2.4 | 2.5 | 2.1 | 2.5 | 2.4 | 3.0 | 2.2 | 2.4 | 2.5 | 2.7 | 2.2 | 2.5 | 2.3 | 3.2 | 3.1 | 2.8 |
| Profit before tax | 0.9 | -2.8 | -3.1 | -4.8 | 0.6 | 1.8 | 1.2 | 0.5 | 2.0 | 2.4 | 2.3 | 0.7 | 0.6 | 1.1 | 2.4 | 0.4 | 1.6 | 1.3 | 5.8 | 0.6 | 1.4 | 0.6 | 2.6 | 0.2 | 0.7 | 1.8 | 3.2 | 1.1 |
| Tax | 1.2 | -0.8 | 0.6 | -0.1 | 0.3 | 1.3 | 0.8 | -3.0 | 0.7 | 1.9 | 0.1 | 0.4 | 0.5 | 0.5 | 0.8 | 0.3 | 0.6 | 0.4 | 0.2 | 0.4 | 0.3 | 0.1 | -2.8 | 0.0 | 0.0 | 0.0 | -0.4 | 0.0 |
| Net profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | 0.4 | 0.0 | 3.6 | 1.4 | 0.6 | 2.0 | 0.3 | 0.0 | 0.6 | 0.0 | 0.1 | 0.9 | 0.9 | 5.5 | 0.3 | 1.0 | 0.5 | 6.7 | 0.2 | 0.7 | 1.8 | 3.6 | 1.1 |
| EPS ₹ | 0.26 | -1.40 | 2.62 | -3.00 | 0.60 | 0.30 | 0.22 | 2.52 | 0.97 | 0.32 | 1.33 | 0.19 | 0.07 | 0.38 | 1.03 | 0.06 | 0.62 | 0.54 | 3.73 | 0.16 | 0.65 | 0.33 | 3.40 | 0.13 | 0.45 | 1.12 | 2.26 | 0.71 |
| Revenue YoY | — | — | — | — | — | 43.5% | 46.0% | 109.7% | 4.0% | 9.7% | 4.6% | — | 12.1% | 10.8% | 11.3% | 0.8% | 22.9% | 6.6% | 14.8% | 5.6% | -20.4% | -10.4% | -13.5% | -11.4% | 0.4% | 19.9% | 2.7% | 34.5% |
| Profit YoY | — | — | — | — | — | — | — | — | 228.6% | — | -45.0% | — | -100.0% | -10.9% | -100.0% | -71.4% | — | 56.1% | — | 225.0% | 9.5% | -46.1% | 23.0% | -19.2% | -31.7% | 270.8% | -46.7% | 433.3% |
Earlier results (standalone, Sep '07 – Dec '17)
₹ crore · from BSE, before the NSE XBRL filings beginBal Pharma Limited reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.
Full years
| FY09† | FY10† | FY11† | FY12† | FY13† | FY14† | FY15† | FY16† | FY17† | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 106.6 | 108.1 | 116.9 | 141.1 | 147.9 | 178.9 | 187.1 | 197.7 | 230.9 |
| Operating profit | 9.7 | 6.3 | 9.4 | 12.6 | 17.2 | 17.9 | 17.5 | 17.1 | 19.6 |
| Operating margin | 9.1% | 5.8% | 8.0% | 8.9% | 11.6% | 10.0% | 9.4% | 8.7% | 8.5% |
| Other income | 0.1 | — | 0.5 | 0.7 | 0.7 | 0.7 | 1.2 | 1.5 | 3.4 |
| Interest | 3.9 | 6.2 | 5.8 | 6.1 | 8.0 | 7.2 | 6.5 | 6.5 | 8.5 |
| Depreciation | 1.8 | 2.8 | 3.0 | 3.6 | 4.8 | 4.7 | 7.0 | 7.0 | 6.5 |
| Profit before tax | 4.1 | -0.7 | 1.1 | 3.6 | 5.1 | 6.6 | 5.2 | 5.2 | 8.1 |
| Tax | 1.1 | 0.6 | 0.6 | -0.2 | 0.8 | 1.6 | 1.2 | 2.4 | 3.1 |
| Net profit | 3.0 | -1.2 | 0.5 | 3.8 | 4.3 | 5.1 | 4.0 | 2.8 | 5.0 |
Quarters
| SEP '07† | DEC '07† | MAR '08† | JUN '08† | SEP '08† | DEC '08† | MAR '09† | JUN '09† | SEP '09† | DEC '09† | MAR '10† | JUN '10† | SEP '10† | DEC '10† | MAR '11† | JUN '11† | SEP '11† | DEC '11† | MAR '12† | JUN '12† | SEP '12† | DEC '12† | MAR '13† | JUN '13† | SEP '13† | DEC '13† | MAR '14† | JUN '14† | SEP '14† | DEC '14† | MAR '15† | JUN '15† | SEP '15† | DEC '15† | MAR '16† | JUN '16† | SEP '16† | DEC '16† | MAR '17† | JUN '17† | SEP '17† | DEC '17† | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23.9 | 23.5 | 23.0 | 28.4 | 26.1 | 26.2 | 25.9 | 18.2 | 29.5 | 30.5 | 29.8 | 27.6 | 22.6 | 28.7 | 38.0 | 29.0 | 35.2 | 37.1 | 39.8 | 30.0 | 39.8 | 35.4 | 42.8 | 37.7 | 47.9 | 44.2 | 49.1 | 42.3 | 49.8 | 42.9 | 52.0 | 41.3 | 55.7 | 46.1 | 54.5 | 43.6 | 65.5 | 58.4 | 63.4 | 45.4 | 54.5 | 51.9 |
| Operating profit | 3.1 | 2.4 | 0.1 | 3.8 | 2.8 | 2.8 | 0.2 | 0.7 | 1.6 | 0.1 | 3.9 | 2.0 | -0.1 | 1.9 | 5.6 | 2.4 | 2.9 | 2.7 | 4.5 | 3.0 | 4.2 | 4.3 | 5.8 | 4.4 | 4.5 | 4.5 | 4.4 | 4.0 | 4.8 | 3.8 | 5.0 | 3.4 | 4.9 | 6.0 | 2.8 | 3.4 | 6.0 | 5.4 | 4.8 | 3.5 | 5.5 | 6.0 |
| Operating margin | 12.8% | 10.3% | 0.6% | 13.4% | 10.7% | 10.9% | 1.0% | 3.6% | 5.6% | 0.4% | 13.1% | 7.3% | -0.6% | 6.5% | 14.8% | 8.2% | 8.4% | 7.3% | 11.4% | 10.0% | 10.5% | 12.2% | 13.5% | 11.8% | 9.4% | 10.3% | 9.0% | 9.4% | 9.6% | 8.8% | 9.6% | 8.2% | 8.8% | 13.0% | 5.2% | 7.9% | 9.2% | 9.2% | 7.5% | 7.7% | 10.1% | 11.5% |
| Other income | 0.0 | 0.0 | — | 0.0 | 0.0 | 0.0 | 0.1 | — | 0.0 | 0.7 | -0.6 | 0.0 | 0.1 | 0.0 | 0.3 | 0.1 | 0.1 | 0.1 | 0.3 | 0.1 | 0.1 | 0.1 | 0.4 | 0.1 | 0.1 | 0.1 | 0.4 | 0.1 | 0.4 | 0.0 | 0.7 | 0.2 | 0.8 | 0.1 | 0.4 | 0.8 | 1.4 | 0.0 | 1.2 | 0.8 | 1.0 | 0.1 |
| Interest | 0.7 | 0.6 | 0.7 | 0.9 | 1.0 | 1.1 | 0.9 | 1.6 | 1.5 | 1.6 | 1.4 | 1.6 | 1.1 | 1.4 | 1.6 | 1.5 | 1.4 | 1.6 | 1.6 | 1.9 | 2.2 | 1.9 | 2.0 | 1.8 | 1.8 | 1.8 | 1.8 | 1.6 | 1.9 | 1.6 | 1.4 | 1.3 | 1.4 | 1.7 | 2.1 | 1.9 | 2.2 | 2.0 | 2.3 | 1.9 | 2.4 | 2.3 |
| Depreciation | 0.4 | 0.4 | 0.5 | 0.4 | 0.4 | 0.4 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.8 | 0.7 | 0.7 | 0.7 | 1.4 | 1.0 | 1.0 | 1.0 | 1.8 | 1.5 | 1.1 | 1.1 | 1.0 | 1.1 | 1.1 | 1.2 | 3.6 | 1.6 | 1.5 | 1.6 | 2.2 | 1.5 | 1.4 | 1.3 | 2.2 | 1.4 | 1.8 | 1.6 |
| Profit before tax | 1.9 | 1.4 | -1.0 | 2.5 | 1.4 | 1.4 | -1.2 | -1.6 | -0.6 | 0.4 | 1.2 | -0.3 | -1.8 | -0.2 | 3.5 | 0.3 | 0.9 | 0.5 | 1.9 | 0.3 | 1.1 | 1.4 | 2.3 | 1.2 | 1.8 | 1.7 | 1.9 | 1.3 | 2.2 | 1.0 | 0.6 | 0.7 | 2.8 | 2.8 | -1.1 | 0.8 | 3.8 | 2.1 | 1.4 | 1.0 | 2.3 | 2.2 |
| Tax | 0.3 | 0.3 | 0.4 | 1.0 | 0.2 | 0.2 | -0.3 | 0.1 | 0.2 | 0.3 | 0.0 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | -0.8 | 0.3 | 0.1 | 0.2 | 0.4 | 0.2 | 0.2 | 0.4 | 0.3 | 0.6 | 0.3 | 0.5 | 0.3 | 0.1 | 0.2 | 0.7 | 0.8 | 0.7 | 0.2 | 1.1 | 0.5 | 1.2 | 0.3 | 0.7 | 0.4 |
| Net profit | 1.6 | 1.1 | -1.5 | 1.6 | 1.2 | 1.2 | -0.9 | -1.7 | -0.9 | 0.1 | 1.2 | -0.5 | -2.0 | -0.3 | 3.3 | 0.2 | 0.6 | 1.3 | 1.6 | 0.2 | 0.9 | 1.0 | 2.1 | 0.9 | 1.4 | 1.4 | 1.4 | 1.0 | 1.7 | 0.8 | 0.6 | 0.5 | 2.1 | 2.0 | -1.8 | 0.6 | 2.7 | 1.5 | 0.2 | 0.7 | 1.7 | 1.7 |
| EPS ₹ | 1.57 | 1.10 | -1.40 | 1.49 | 1.12 | 1.13 | -0.87 | -1.62 | -0.83 | 0.10 | 1.17 | -0.49 | -1.90 | -0.28 | 3.16 | 0.17 | 0.61 | 1.24 | 1.54 | 0.18 | — | 0.99 | 2.01 | 0.86 | 1.33 | 1.32 | 1.25 | 0.78 | 1.32 | 0.81 | 0.43 | 0.37 | 1.62 | 1.57 | -0.14 | 0.42 | 0.80 | 1.07 | 0.13 | 0.50 | 1.18 | 1.23 |
| Revenue YoY | — | — | — | — | 9.4% | 11.4% | 12.3% | -35.8% | 13.2% | 16.7% | 15.2% | 51.2% | -23.4% | -6.0% | 27.3% | 5.1% | 55.4% | 29.4% | 4.8% | 3.5% | 13.0% | -4.8% | 7.7% | 25.7% | 20.4% | 25.1% | 14.6% | 12.3% | 4.1% | -3.0% | 6.1% | -2.5% | 11.9% | 7.4% | 4.8% | 5.6% | 17.6% | 26.7% | 16.2% | 4.2% | -16.7% | -11.1% |
| Profit YoY | — | — | — | — | -28.7% | 2.6% | — | -209.0% | -174.4% | -91.5% | — | — | — | -390.0% | 169.1% | — | — | — | -50.8% | 5.6% | 45.3% | -20.6% | 30.1% | 384.2% | 51.6% | 33.7% | -35.8% | 6.5% | 20.6% | -43.9% | -58.8% | -51.0% | 22.4% | 157.7% | -416.1% | 22.9% | 27.9% | -24.4% | — | 20.3% | -37.2% | 14.5% |
Returns & margins
trailing-twelve-month, per quarter| JUN '20 | SEP '20 | DEC '20 | MAR '21 | JUN '22 | SEP '22 | DEC '22 | MAR '23 | JUN '23 | SEP '23 | DEC '23 | MAR '24 | JUN '24 | SEP '24 | DEC '24 | MAR '25 | JUN '25 | SEP '25 | DEC '25 | MAR '26 | JUN '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | 4.8% | 4.7% | 1.3% | 1.0% | 2.5% | 3.0% | 10.7% | 10.9% | 11.1% | 10.5% | 11.0% | 10.9% | 10.4% | 12.0% | 7.6% | 8.8% |
| ROCE | — | — | — | — | — | 8.1% | 7.8% | 8.7% | 9.2% | 9.7% | 10.1% | 11.6% | 12.0% | 11.0% | 11.3% | 9.7% | 9.4% | 9.0% | 9.4% | 9.4% | 10.0% |
| Net margin | 0.2% | 0.4% | 0.4% | 1.8% | 1.5% | 1.0% | 1.0% | 0.3% | 0.2% | 0.5% | 0.6% | 2.2% | 2.2% | 2.4% | 2.3% | 2.8% | 2.9% | 2.8% | 3.0% | 2.0% | 2.2% |
| EBITDA margin | 4.7% | 7.0% | 8.8% | 9.8% | 7.5% | 7.1% | 6.9% | 8.3% | 8.7% | 8.8% | 9.2% | 9.3% | 9.2% | 9.7% | 10.0% | 9.8% | 9.9% | 9.2% | 9.4% | 10.2% | 10.1% |
| Debt / equity | — | — | — | — | — | 2.27 | 2.27 | 2.05 | 2.05 | 2.23 | 2.23 | 2.02 | 2.02 | 2.25 | 2.25 | 1.94 | 1.94 | 1.98 | 1.98 | 1.94 | 1.94 |
| Interest coverage | 0.15 | 0.53 | 0.90 | 1.34 | 1.75 | 1.59 | 1.43 | 1.39 | 1.33 | 1.38 | 1.38 | 1.59 | 1.58 | 1.57 | 1.49 | 1.31 | 1.28 | 1.24 | 1.32 | 1.35 | 1.40 |
| Asset turnover | — | — | — | — | — | 0.99 | 1.01 | 0.97 | 0.97 | 0.98 | 0.99 | 1.06 | 1.07 | 0.96 | 0.93 | 0.90 | 0.88 | 0.84 | 0.89 | 0.83 | 0.89 |
Balance sheet
equity vs borrowings over time · ₹ crore| SEP '22 | MAR '23 | SEP '23 | MAR '24 | SEP '24 | MAR '25 | SEP '25 | MAR '26 | |
|---|---|---|---|---|---|---|---|---|
| Share capital | 15.6 | 15.7 | 15.7 | 15.8 | 15.9 | 15.9 | 15.9 | 15.9 |
| Other equity / reserves | 44.8 | 48.1 | 47.6 | 53.5 | 52.9 | 61.5 | 62.4 | 66.3 |
| Total equity | 60.4 | 63.8 | 63.3 | 69.3 | 68.8 | 77.4 | 78.3 | 82.2 |
| Borrowings | 137.3 | 131.0 | 141.1 | 139.7 | 154.9 | 150.4 | 154.9 | 159.5 |
| Current liabilities | 187.3 | 209.3 | 249.5 | 203.9 | 220.7 | 219.5 | 228.9 | 249.2 |
| Non-current liabilities | 44.1 | 40.1 | 17.1 | 47.2 | 50.0 | 38.8 | 42.1 | 44.1 |
| Total assets | 291.7 | 313.2 | 329.8 | 320.4 | 339.5 | 335.7 | 349.4 | 375.5 |
| Property, plant & equipment | 56.2 | 62.2 | 61.1 | 61.6 | 63.9 | 71.0 | 76.2 | 76.8 |
| Capital work-in-progress | 0.0 | 0.0 | 0.1 | 0.5 | 1.7 | 2.8 | 3.0 | 7.4 |
| Investments | 0.0 | 0.0 | 0.0 | 6.8 | 11.0 | 2.5 | 0.4 | 2.1 |
| Inventories | 86.2 | 98.0 | 105.7 | 87.8 | 89.9 | 103.0 | 112.7 | 116.4 |
| Receivables | 85.7 | 94.0 | 102.9 | 99.6 | 103.2 | 92.4 | 90.8 | 93.6 |
| Cash & equivalents | 1.1 | 1.5 | 1.4 | 4.2 | 1.9 | 1.8 | 1.6 | 2.3 |
Cash flow
annual · ₹ crore · line = free cash flow| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Cash from operations | 32.0 | 23.0 | 329.2 | 20.7 | 7.9 |
| Cash from investing | 11.3 | 18.4 | 0.0 | -18.1 | -9.8 |
| Cash from financing | 1.1 | 0.0 | 34.6 | 0.3 | -27.3 |
| Capex | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Free cash flow | 32.0 | 23.0 | 329.2 | 20.7 | 7.9 |
| Dividends paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Where the assets sit
Mar '26 · ₹ croreFixed assets (PPE)₹76.8 cr20%
CWIP₹7.4 cr2%
Investments₹2.1 cr1%
Inventories₹116.4 cr31%
Receivables₹93.6 cr25%
Cash & equivalents₹2.3 cr1%
Other assets₹77.0 cr21%
Peer comparison
largest in Unclassified · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Avantel Limited | 36,86,04,549 | 138.69 | — | 1059360.68 | 0.0% |
| Ducol Organics And Colours Limited | 19,55,275 | 120.00 | — | 20089.13 | 0.0% |
| Jio Platforms Limited | 12,57,181 | 1,406.40 | — | 3.57 | — |
| SBI Funds Management Limited | 1,01,750 | 499.55 | — | — | — |
| Tamilnadu Telecommunication Limited | 91,314 | 9.93 | — | — | — |
| Manipal Health Enterprises Limited | 76,294 | 646.70 | — | — | — |
| INDO-MIM Limited | 59,042 | 1,219.50 | — | — | — |
| AvenuesAI Limited | 45,138 | 129.25 | 153.6 | 9.51 | 6.2% |
| Dhoot Transmission Limited | 32,761 | 1,601.60 | — | 8.11 | — |
| 3M India Limited | 31,071 | 27,570.00 | 53.8 | 17.57 | 32.7% |
| Bal Pharma Limited | 130 | 81.55 | 18.0 | 1.58 | 8.8% |
StoxGud checklist: Bearish setup · 3/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
1 month-17.3%
6 months+3.9%
1 year-1.7%
3Y CAGR-4.0%
5Y CAGR-3.8%
10Y CAGR-3.0%
50-day avg₹94.76
200-day avg₹82.87
RSI (14)29
FAQs
What is the share price of Bal Pharma Limited?
Bal Pharma Limited (BALPHARMA) closed at ₹81.55 on NSE on 06 Nov 2026.
What is the market cap of Bal Pharma Limited?
₹130 crore at the latest close.
What is the P/E ratio of Bal Pharma Limited?
18.0, on trailing-twelve-month earnings from its filings.
How fast is Bal Pharma Limited growing?
Bal Pharma Limited: revenue has compounded at 0.8% a year over three years. Latest-quarter revenue is up 34.5% year on year, profit up 433.3%.
How profitable is Bal Pharma Limited?
On a trailing-twelve-month basis return on equity is 8.8%, return on capital employed 10.0%, operating margin 10.1%, net margin 2.2%.
How much debt does Bal Pharma Limited have?
Bal Pharma Limited is highly geared: debt to equity is 1.94 with borrowings of ₹160 cr against cash of ₹2 cr (balance sheet of 2026-03-31). Operating profit covers interest 1.4 times.
Financials parsed from Bal Pharma Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '18, annual from FY18, balance sheet from Sep '22. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.
Bal Pharma Limited · advanced chart